Agilent Technologies Introduces New Chromatography Data System
On November 16th, Agilent Technologies (Santa Clara, California) released their brand new, state-of-the-art, next gen chromatography data system (CDS), Agilent OpenLAB CDS.
On November 16th, Agilent Technologies (Santa Clara, California) released their brand new, state-of-the-art, next gen chromatography data system (CDS), Agilent OpenLAB CDS. The system features major improvements to Agilent’s current ChemStation and EZChrom Elite CDS platforms, and the new OpenLAB CDS is backward compatible with both of them.
“The new system is designed from a customer-centric perspective and dramatically improves productivity and quality across the entire customer organization -- from scientists and system administrators through lab managers and IT executives,” said Bruce von Herrmann, Vice President and General Manager of Agilent Software and Informatics.
“Our customers told us they wanted this new functionality without any changes to their existing workflows, and that's what we're delivering. We have engaged a number of customers throughout the design, development and testing phases of OpenLAB CDS,” Herrmann added.
OpenLAB supports both liquid and gas chromatographs from multiple different sources, enabling customers to have the freedom of choosing the vendor of their preference while also providing an easy way for labs to switch over from other data platforms.
According to the company, one of the major benefits of the new OpenLAB system is its intelligent reporting that allows users to generate analytical reports with whatever results they need and in any kind of format, enabling the reports to be precisely created to meet the needs of the user.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
